Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 20/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530655 | 0.83 | NR1H2 (0.72) | NR1H2NR1H3 | |
| SCHEMBL5532279 | 0.75 | NR1H2 (0.75) | NR1H2NR1H3 | |
| SCHEMBL14367891 | 0.74 | NR1H2 (0.75) | NR1H2NR1H3 | |
| SCHEMBL5620968 | 0.74 | NR1H2 (0.68) | NR1H2NR1H3 | |
| SCHEMBL17220656 | 0.74 | NR1H2 (0.67) | NR1H2NR1H3 | |
| SCHEMBL31416526 | 0.73 | NR1H2 (0.64) | NR1H2NR1H3 | |
| SCHEMBL5937425 | 0.73 | NR1H2 (0.64) | NR1H2NR1H3 | |
| SCHEMBL5621533 | 0.73 | NR1H2 (0.74) | NR1H2NR1H3 | |
| SCHEMBL19181943 | 0.73 | NR1H2 (0.66) | NR1H2NR1H3 | |
| SCHEMBL981026 | 0.73 | NR1H2 (0.69) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1844011-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006081343-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR2, PTGDR, CYSLTR2 | NR1H2 49/4885NR1H3 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.